HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haaga, J. R. Articles by Bellmore, M. Search for Related Content PubMed PubMed Citation Articles by Haaga, J. R. Articles by Bellmore, M. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

Intracavitary Urokinase for Enhancement of Percutaneous Abscess Drainage

Phase II Trial

¹ Department of Radiology, University Hospitals of Cleveland, Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH 44106-5056.
² Department of Radiology, University of Tennessee Medical Group, Inc., and the University of Tennessee, 800 Madison Ave., Memphis, TN 38163.
³ Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115.
⁴ Block, McGibany, Bellmore & Associates, Inc., 3609 Woodvalley Dr., Baltimore, MD 21208.

OBJECTIVE. To evaluate the effectiveness of urokinase as an abscess-cavity irrigant during percutaneous abscess drainage.

SUBJECTS AND METHODS. In a prospective study, approved by the Food and Drug Administration and the review board at our institution, urokinase and saline were used as abscess-cavity irrigants. In the study group of 42 patients, half the patients were randomly placed into the urokinase group and the other half were placed into the control saline group. Doses used varied with the size of the abscess. Data collected from patient charts were evaluated with standard statistical methods.

RESULTS. The results indicate definite benefits of the urokinase treatment. The length of stay (p = 0.0025) and treatment costs (p = 0.0021) were significantly less for the urokinase group. Other clinical parameters, including the febrile course, elevated WBC, and days of drainage, trended in a favorable fashion.

CONCLUSION. Urokinase injected intracavitarily is an effective technique for shortening the treatment time and improves the clinical course for patients treated with percutaneous drainage techniques.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. D. Berna-Serna, J. D. Berna-Mestre, P. J. Galindo, and M. Madrigal Use of Urokinase in Percutaneous Drainage of Large Breast Abscesses J. Ultrasound Med., April 1, 2009; 28(4): 449 - 454. [Abstract] [Full Text] [PDF]

				M. D. Beland, D. A. Gervais, D. A. Levis, P. F. Hahn, R. S. Arellano, and P. R. Mueller Complex Abdominal and Pelvic Abscesses: Efficacy of Adjunctive Tissue-Type Plasminogen Activator for Drainage Radiology, May 1, 2008; 247(2): 567 - 573. [Abstract] [Full Text] [PDF]

				D. A. Gervais, S. D. Brown, S. A. Connolly, S. L. Brec, M. G. Harisinghani, and P. R. Mueller Percutaneous Imaging-guided Abdominal and Pelvic Abscess Drainage in Children RadioGraphics, May 1, 2004; 24(3): 737 - 754. [Abstract] [Full Text] [PDF]